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Denise Neumann and colleagues attempted to investigate whether dialysis modality 
(peritoneal dialysis compared to hemodialysis) could affect changes in neurocognition. 
Their study highlights all the challenges around such research. These include using 
appropriate tests to investigate cognition, challenges of comparing people on different 
modalities considering that different types of people chose these, and reasons for drop-
out that affect assessment of neurocognition during follow-up. More studies in this area 
are needed to inform patient choice. 
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Although the incidence of older patients starting dialysis has not changed in the past 
years, due to demographic change and the ageing population, older people (aged 75+) 
form a bigger part of the prevalent population on dialysis.1  
We know that people with CKD have high prevalence of multimorbidity.2 Compared to 
the general population of the same age and sex, there appears to be a higher prevalence of 
cognitive impairment amongst those with reduced eGFR.3 A recent study indicates that 
up to 70% of patients on hemodialysis (HD) may be affected.4  
 
To date there is little evidence to help patients decide the dialysis modality. Patients may 
make differing choices if they knew that dialysis affects cognition. Data comparing 
cognition on different dialysis modalities are needed, and in this issue Neumann et al. 
have attempted to address this question.5 
 
In order to appreciate the challenges of such research it may be useful to contrast the 
ideal theoretical study design of such a question with the practical challenges that 
Neumann et al. encountered during their study.  
 
In an ideal study investigating how dialysis modality affects cognition, one would 
randomise people starting dialysis to either hemodialysis or peritoneal dialysis, quantify 
cognition before dialysis start at baseline and then several times during follow-up. Early 
changes in cognition may be due to treating uraemia, therefore, a long-term follow-up of 
at least a year or even more would be needed. Power calculations would need to be 
adjusted for the high early mortality in people starting dialysis. In reality to date there has 
been no trial successful in recruiting sufficient numbers of participants who agree to be 
randomized to different dialysis modalities, so clearly such a randomized trial is not 
feasible.  
 
An observational study of this question would need to be ideally as similar as possible to 
the suggested hypothetical trial. The investigator would attempt to recruit patients starting 
dialysis, and try to ensure that those on differing modalities are as similar in comorbidity 
profile and baseline cognition as much as possible. The investigator would then 
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investigate cognition at follow-up, to see how cognition is affected by dialysis modality, 
adjusted for confounding factors. As outlined above, such a study would need to take into 
account the early mortality in dialysis starters, not over-interpret early changes, and 
therefore require sufficiently long of follow-up of one or more years.  
 
Neumann et al capitalized in their work on an existing German multicenter study of 
prevalent dialysis patients who were recruited approximately 6-24 months after starting 
dialysis.5 Such a design means that those patients who died during the early phases of 
dialysis are excluded, and that patients are likely to be in steady state. The baseline 
assessment of these patients took place in May 2014-2015, and follow-up assessment a 
year later.5 
 
Patients who undergo cognitive assessments need to be able to do these assessments. This 
posed a significant practical challenge:5  
Of 767 patients who were approached for cognitive assessments as part of the study, 366 
patients of whom 304 were on HD had to be excluded at baseline. Visual impairment was 
the most common reason (48%), lack of motivation was prevalent in 30%, 12% had 
motor conditions, and 5% were unable to follow the instructions.  
Of the 401 patients who then had a baseline assessment of cognitive function, there were 
further 130 patients who were not followed up at 12 months, 16% of these died (9% on 
HD, and 7% on peritoneal dialysis (PD)), and 35% were transplanted or switched dialysis 
modality (4% on HD, and 31% on PD). A quarter of patients had to be excluded during 
the one year follow-up because they developed visual problems and motor conditions 
(21% on HD and 4% on PD).  
Patients on HD are likely to be visually impaired and have motor conditions, whilst PD 
patients cannot do PD unless they can operate the dialysis equipment. Patients on PD are 
also more likely to be transplanted during follow-up, whilst death rates were broadly 
similar. All in all this shows the challenges of assessing long-term cognitive function in 
patients on dialysis, which relate to disability and competing risks of death and 
transplantation. 
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Neumann et al report data on the cognitive assessment in the 271 patients who had 
complete baseline and follow-up cognitive assessment data.5 Cognitive function was 
assessed by patient reported cognitive function (KDQOL-SFtm25 3-item subscale) and two 
tests assessing selective attention (d2-R testing) and executive functioning (TMT-B), by 
appropriately trained staff. A number of sensitivity analyses found no evidence for 
dialysis features (e.g timing relative to start of haemodialysis) affecting test quality in 
patients.5  
 
The authors wanted to ensure that the patients on HD and PD were comparable in terms 
of their psychotropic medication, dialysis vintage and comorbidity profile. In view of the 
small numbers of the sample, they used a technique called propensity score matching to 
ensure that these features are balanced in both groups at baseline. This resulted in 62 
patients on HD and 12 patients on PD being dropped from further analysis as they could 
not be matched to a comparable patient on the other dialysis modality. This shows that 
patients on HD and PD when established on their respective modality are quite distinct in 
their comorbidity profile and that crude comparisons of cognition are not meaningful as 
they may be due to case-mix as opposed to the effect of the modality itself.  
 
They then carried out a random effects analysis in this matched cohort. This analysis was 
taking account of the correlation of the two cognitive scores at baseline and follow-up 
within the same patient. The authors then plotted predicted population mean scores at 
baseline and follow-up. Overall, using the objective tests (TMT-B and d2-R) all patients 
tended to perform better at the second measurement when compared to the first, with no 
evidence that this increase in performance differed between dialysis modalities. It is 
unlikely that patients remember how to do these tests well over a year, and so this finding 
may be a true change in functioning. At both time points, after having taken account of 
baseline differences between these two groups using propensity score matching, those on 
PD showed marked better performance than those on HD. In contrast self-reported 
functioning decreased, and those on HD report somewhat better scores than those on PD 
though overall the difference appears to have less clinical meaning when contrasted with 
the magnitude of observed differences in the objective cognitive functioning tests. The 
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self-reported cognitive functioning did not correlate with the objective psychometric tests 
at all. There may non-differential misclassification of the self-reported questionnaire data.  
 
This descriptive study shows the difficulties in studying cognition in dialysis patients, 
with a large number of patients unable to undergo psychometric tests over a prolonged 
period, especially those on HD, and the importance that case-mix plays on any 
comparison of cognition between dialysis modalities. We can conclude that if a dialysis 
patient is fit enough to undergo cognitive testing and if such a patient remains fit and 
survives the following year without developing motor or visual problems, then this 
patient may have stable or improved cognition on objective testing. Even if we take 
baseline comorbidity into account, patients who are stable on PD tend to have better 
cognition than patients on HD with similar comorbidity profile. These findings may be 
affected by residual confounding, despite the statistical state of the art efforts to control 
for this. We cannot exclude that the differences observed in this study are due to patients 
with better cognitive function who feel competent to do PD preferentially chosing PD 
over HD to maintain a flexible life-style. From this study, we learn that clinicians cannot 
rely on self-report alone to assess cognitive functioning over time, as what patients report 
may not relate to the objective measures.  
 
Clearly, more research is needed on cognitive function using patients starting dialysis 
with a longer follow-up allowing for competing risks of death, transplantation and the 
development of visual and motor impairment over time. Neumann et al have made a start 
on this journey and shown that there are a number of practical difficulties associated with 
this work. 
 
Figure 1. Conceptual diagram of study of Neumann et al. 
The association of interest is highlighted with a blue arrow, drop out is captured by the 
red box and arrows, measured confounders are indicated by the black boxes, unmeasured 
factors are in the brown box. The confounding pathways which are analytically removed 
by propensity score matching are signified with crosses.  
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